Prenetics to Report Q4 and Full Year 2025 Financial Results on Feb 18, 2026 and Host Earnings Conference Call
Rhea-AI Summary
Prenetics (NASDAQ: PRE) will release its Q4 and full year 2025 financial results for the period ended December 31, 2025 before market open on Wednesday, February 18, 2026.
The company will host an earnings conference call the same day at 10:00 a.m. Eastern Time with a Q&A session; an audio replay will be available on the investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – PRE
On the day this news was published, PRE declined 0.14%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $506K from the company's valuation, bringing the market cap to $361M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PRE is up 1.47% while peers show mixed moves: BNR -3.09%, MDXH -3.21%, FONR +0.32%, BDSX +2.88%, XGN +3.24%. With no peers in the momentum scanner and no same-day peer headlines, today’s action appears more company-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Business divestiture | Positive | +2.8% | Sale of Europa business and focus on IM8 with strong liquidity metrics. |
| Jan 05 | Warrant exchange | Positive | +0.4% | High warrant exchange participation reducing potential dilution from October 2025 financing. |
| Dec 30 | Capital allocation shift | Positive | -3.3% | Cessation of Bitcoin purchases and refocus of capital on IM8 brand growth. |
| Dec 23 | Warrant restructuring | Positive | -6.9% | Voluntary warrant exchange to simplify capital structure and cut dilution risk. |
| Nov 25 | Conference participation | Neutral | +8.6% | Announcement of December investor conference appearances and related presentations. |
Recent news often triggers sizable moves, with positive balance-sheet and capital-structure updates sometimes met by negative or mixed price reactions.
Over the past few months, Prenetics has focused on portfolio optimization and capital structure. It divested Europa for up to $13 million, following the $72 million ACT Genomics sale, and highlighted over $70 million cash, 510 BTC, and $118 million total liquidity. Multiple warrant exchange steps reduced potential dilution, while IM8 growth and conference participation supported the equity story. Today’s earnings-date announcement follows this sequence of balance-sheet and strategic updates.
Market Pulse Summary
This announcement sets the timetable for Q4 and full-year 2025 results on February 18, 2026, with an earnings call at 10:00 a.m. ET. It follows months of balance-sheet strengthening, asset sales, and warrant exchanges aimed at refining Prenetics’ capital structure and focusing on IM8. Investors may watch for cash levels, IM8 revenue traction, and any updates following the recent strategic transactions when the detailed results are released.
AI-generated analysis. Not financial advice.
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a leading health sciences company and parent of the IM8 premium health and longevity brand, today announced it will release financial results for the fourth quarter and full year 2025 ended December 31, 2025 before market open on Wednesday, February 18, 2026. The Company will also hold its earnings conference call the same day at 10:00 a.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.
| Date: | Wednesday, February 18, 2026 |
| Time: | 10:00 a.m. Eastern Time |
| Dial-in: | 1-877-425-9470 |
| International Dial-in: | 1-201-389-0878 |
| Webcast | PRE Conference Call |
An audio replay of the webcast will be available on the Company’s investor relations website at https://ir.prenetics.com/.
About Prenetics
Prenetics (NASDAQ: PRE) is a leading health sciences company dedicated to advancing human health and longevity. The Company’s flagship consumer brand, IM8, co-founded with David Beckham and championed by World No. 1 tennis player Aryna Sabalenka, is redefining the premium daily nutrition category through science-backed formulations and global brand partnerships. Since its launch, IM8 has become one of the fastest-growing brands in consumer health, surpassing
About IM8
IM8 is the pinnacle of premium core nutrition, born from a collaboration between David Beckham as a co-founding partner, and an elite team of scientists spanning medical professionals, academia and space science. Combining cutting-edge science with nature’s most potent ingredients, IM8 delivers a holistic, science-backed approach to health, empowering you to live your most vibrant life. IM8’s flagship product, Daily Ultimate Essentials is an all-in-one powder supplement engineered to replace 16 different supplements in a delicious drink and is NSF Certified for Sport, non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors or sweeteners. IM8 is a subsidiary of Prenetics (NASDAQ: PRE), a leading global health sciences company dedicated to advancing consumer health. To learn more about IM8, please visit www.IM8health.com.
Investor Relations Contact:
investors@prenetics.com
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance
angela.hm.cheung@prenetics.com
FAQ
When will Prenetics (PRE) report its Q4 and full year 2025 results?
What time is the Prenetics (PRE) earnings conference call on February 18, 2026?
How can investors join the Prenetics (PRE) earnings call and webcast?
Will Prenetics (PRE) provide a replay of the February 18, 2026 earnings call?
What topics will Prenetics (PRE) cover during the February 18, 2026 call?
